Allelic ratio of KRAS mutations in pancreatic cancer
KRAS is not simply mutated or wild type in pancreatic ductal adenocarcinoma (PDAC); actually, it has never been. More than 90% of PDACs carry mutated KRAS alleles; however, the impact on PDAC biology may vary with the tumor-specific allelic ratio and dosage of mutated KRAS.
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
16 March 2015
|
| In: |
The oncologist
Year: 2015, Jahrgang: 20, Heft: 4, Pages: e8-e9 |
| ISSN: | 1549-490X |
| DOI: | 10.1634/theoncologist.2014-0408 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1634/theoncologist.2014-0408 Verlag, lizenzpflichtig, Volltext: https://theoncologist.onlinelibrary.wiley.com/doi/abs/10.1634/theoncologist.2014-0408 
|
| Verfasserangaben: | Jochen K. Lennerz, Albrecht Stenzinger |
| Zusammenfassung: | KRAS is not simply mutated or wild type in pancreatic ductal adenocarcinoma (PDAC); actually, it has never been. More than 90% of PDACs carry mutated KRAS alleles; however, the impact on PDAC biology may vary with the tumor-specific allelic ratio and dosage of mutated KRAS. |
|---|---|
| Beschreibung: | Gesehen am 17.06.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1549-490X |
| DOI: | 10.1634/theoncologist.2014-0408 |